Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jazz Buys Compliance Trouble With FazaClo Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

The schizophrenia drug’s previous owner, Azur Pharma, produced a patient brochure that drew a warning letter FDA’s Office of Prescription Drug Promotion.


Related Content

Teva Cited For Promo Suggesting 14-Year Old Schizophrenia Study Shows Clozapine Superiority
‘Tis The Season… For An FDA Enforcement Letter To Alcon
Jazz Cools On Women’s Health, Sells Unit To Meda
Luvox CR Symptom Benefit Claims Draw DDMAC Warning
Short Attention Span? Shire Cited Again For Out-Of-Bounds ADHD Promotion


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts